AdAlta Ltd (ASX:1AD) CEO Dr Tim Oldham speaks with Proactive after announcing all healthy volunteers in its AD-214 Phase I extension study have successfully received three doses. The milestone allows pharmacokinetic and receptor engagement analysis to be completed on schedule. The results confirm the favourable tolerability profile observed at lower doses. Dr Oldham says the company has also materially progressed several partnering and project financing discussions over the past month to help progress phase II studies.
AdAlta making material progress on partnering talks
